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Apolipoproteins and lipoprotein receptors in glomeruli in human
kidney diseases. This study offers morphological evidence of the in-
volvement of lipid abnormalities in human glomerular injury. Renal
biopsy tissues from patients with several types of glomerular diseases
were immunocytochemically examined using antibodies to apolipopro-
teins (apo) A-I, B-100, and E, and antibodies to low density lipoprotein
(LDL) receptors and scavenger receptors. Immunofluorescent staining
showed the predominant deposition of apo B and apo E in the mesangial
area in mesangial proliferative types of glomerulonephritis; the distri-
bution and staining intensity of these apolipoproteins correlated with
the grade of mesangial proliferation and proteinuria, but were indepen-
dent of plasma lipid levels. Immunoelectron microscopy revealed that
apo B and apo E were distributed in droplets within glomerular
epitheial and mesangial cells or in a granular pattern in the expanded
mesangial matrix. Apo A-I was mainly localized in the visceral epithe-
hal cells of normal human kidneys. Staining for apo A-I was increased
in the glomerular epithelial cells of nephritic kidneys, compared to the
pattern in normal human kidneys, and was decreased in the sclerosed
areas of glomeruli. An immunogold technique revealed the expression
of LDL receptors on the surface membranes of glomerular mesangial
and epithelial cells. Dual immunofluorescent staining showed that apo B
and LDL receptors were occasionally co-localized in nephritic glomer-
uli. Scavenger receptor was detected on the plasma membranes of
mesangial and visceral epithelial cells. The glomerular expression of
scavenger receptor was increased in glomeruli with marked mesangial
proliferation. In addition, the expression of this receptor was intense in
monocytes/macrophages occasionally infiltrating the glomeruli. Our
present findings indicate that in human nephritic kidneys, glomerular
epithelial and mesangial cells express both LDL receptors and scaven-
ger receptors. The accumulation of apolipoproteins, whether receptor-
mediated or mediated by other mechanisms, can occur independently of
plasma lipid levels, and may be associated with mesangial expansion
and proteinuria.
Accumulating evidence indicates that abnormalities of lipid
metabolism are responsible for the progression of glomerular
damage in both immunological and non-immunological types of
renal diseases [1—3]. A hereditary form of lecithin cholesterol
acyltransferase deficiency has been reported to cause glomeru-
lar lipid deposition and progressive renal insufficiency [4].
Abnormal lipid accumulation is found within glomeruli and
tubular cells in various types of human nephritis [5, 6]. Foam
cells, believed to be lipid-laden macrophages, have been iden-
tified in kidney vessels and in the interstitium as well as in
glomeruli [7]. Mesangial cells and glomerular epithelial cells
express surface receptors for low density lipoprotein (LDL) [8,
91, and could, therefore, be affected by abnormal lipid metab-
olism. Experimentally, glomerular injury, including increased
mesangial matrix and cellularity, followed by the appearance of
albuminuria occurs with diet-induced hyperlipidemia [10] and
with endogenous abnormalities in lipid metabolism [111.
The mechanisms of lipid-induced glomerular injury are still
incompletely understood. The apparently infrequent occur-
rence of renal disease in patients with the most common forms
of hyperlipidemia suggests that lipids may cause clinically
important renal injury only when additional predisposing fac-
tors, such as immune-mediated glomerular cell damage, are
present. Based on certain histologic similarities, analogous
pathobiologic mechanisms have been suggested for glomerulo-
sclerosis and atherosclerosis [121. Modified LDL, which is
taken up by tissue macrophages via scavenger receptors and is
an important pathogen in atherosclerosis [13, 141, has been
shown to be cytotoxic to cultured mesangial cells [15, 16], and
could contribute to glomerular damage in nephritis, although
the precise mechanism by which this could occur is unknown.
To further delineate the role of lipid abnormalities in human
glomerular injury, we immunocytochemically evaluated the
glomerular expression of LDL and scavenger receptors, as well
as evaluated the renal deposition of the predominant plasma
lipoproteins A-I, B-l00, and E, which are essential structural
components of high density lipoprotein (HDL), LDL, and very
low-density lipoprotein (VLDL), respectively.
Methods
Patients and tissues
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The kidney tissues used in this study were obtained by
percutaneous needle biopsy or surgical biopsy from 74 patients
with various types of kidney diseases: 30 patients with IgA
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Table 1. Antibodies used in this study
Specificity Antibody Produced by Source
Apo A-I MoAb (ABAI-1) mouse IgG1 Canadian Bioclinical
Apo B-i0O MoAb (AB B-3)
TRIC-labeled
mouse IgG2
goat
Canadian Bioclinical
Binding site
Apo E
LDL receptor
MoAb (AB E-i)
TRIC-labeled
MoAb
mouse IgG1
goat
mouse IgG21
Canadian Bioclinical
Binding site
Amersham
Human scavenger receptor hSRI-2 rabbit Matsumoto et a! [14]
Human monocyte/macrophages
Type IV collagen (7S domain)
FMC 32 (CDT4)
Anti-Leu-M3 (CD14)
MoAB (MAb TV-i)
mouse IgG
mouse IgG2
mouse IgG
AMD
Becton-Dickinson
Scheinman and Tsai [19, 34]
Abbreviations are: MoAb, monoclonal antibody; TRIC, tetramethylrhodamin; AMD, Austrarian Monoclonal Development.
Fig. 1. Indirect immunofluorescent staining with monoclonal antibodies to apo B-100 (A—C) and apo E (D) in patients with IgA nephritis with mild
(A) or marked (B and D) mesangial proliferation, and in a patient with focal glomerular sclerosis (C). A. Apo B is visible in the mesangium, and
staining is weak along the glomerular capillary walls (immunofluorescence score 1). B. Mesangial deposition of apo B is prominent
(immunofluorescence score 2). C. Intense staining for apo B is seen in an almost globally sclerotic glomerulus (immunofluorescence score 2). D.
Positive staining for apo E is prominent in the mesangial area. Original magnification: A—D x400.
nephritis, 15 with mesangial proliferative (non-IgA) glomerulo-
nephritis, 10 with Henoch-Schonlein purpura nephritis (HSPN),
10 with minimal change nephrotic syndrome, 4 with lupus
nephritis (WHO Class IV), and 5with nephrotic syndrome with
focal glomerular sclerosis. Laboratory data including urinaly-
sis, 24-hour urinary protein excretion and creatinine clearance
were collected for each patients. Plasma levels of lipids and
apoproteins were determined using fasting serum samples ob-
tained from 28 patients with mesangial proliferative glomerulo-
nephritis, including 18 patients with IgA nephritis. Lipids and
apoproteins were measured by standard procedures currently
used in Japan; total cholesterol and triglyceride were assayed
with an autoanalyzer, utilizing enzymatic methods. HDL cho-
lesterol was measured after precipitation of LDL and VLDL
cholesterols by a heparin-manganase reagent. Apo A-I, apo B
and apo E were immunoturbidometrically determined using the
reagent kits (ApoAuto "Daiichi", Daiichi Pure Chemical, To-
kyo, Japan) [17].
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Table 2. Results of apo B, apo E, LDL receptor and scavenger receptor immunofluorescent staining in glomeruli of patients with various
types of glomerular diseases
Disease/Mesangial proliferationa
Total no.
of patients
Staining in glomeruli
Apo B" Apo E" LDL receptorb Scavenger receptorc
IgA nephritis 30 18/30 15/30 7/30 3/15
1+ 10 3 2 1 0
2+ 14 9 7 3 1
3+ 6 6 6 3 2
Mesangial proliferative (non-IgA) nephritis 15 10/15 7/15 5/15 2/7
1+ 5 2 1 1 0
2+ 6 4 3 2 0
3+ 4 4 3 2 2
Henoch-SchOnlein purpura nephritis 10 3/10 2/10 1/10 1/5
1+ 3 0 0 0 0
2+ 6 2 1 0 0
3+ 1 1 1 1 1
Nephrotic syndrome
Minimal change 10 1/10 0/10 1/10 1/6
Focal glomerulosclerosis 5 4/5 4/5 3/5 2/5
Lupus nephritis (WHO Class IV) 4 3/4 3/4 2/4 2/4
Total 74 39/74 31/74 19/74 11/42
a Mesangial proliferation was graded as mild (1+), moderate (2+) or marked (3+)b Number of patients with positive staining/number of patients examined by immunofluorescence
Number of patients whose kidney tissues showed increased intensity and distribution of staining compared with normal human kidneys/number
of patients examined by immunofluorescence
Three other kidney specimens were obtained; these were
from patients with renal calculi or renal trauma, and histologi-
cally normal portions were used as normal human kidney
tissue. For light microscopic observation, the tissues were fixed
in 10% buffered formalin and embedded in paraffin. Three
sm-thick sections were stained with hematoxylin and eosin,
periodic acid-Schiff, and methenamine silver. Mesangial prolif-
eration was graded as described previously [18]. Cryostat
sections were stained for neutral lipids with oil red 0.
Antibodies
The monoclonal and polyclonal antibodies used in this study
are listed in Table 1. Antibody to human scavenger receptor
was produced by immunizing rabbits with bovine serum albu-
min-coupled synthetic peptide (hSRI-2) corresponding to the
C-terminus of the collagen-like domain [14]. The following
antibodies were purchased from Cappel (Malvern, Pennsylva-
nia, USA): F(ab')2 fragments of goat anti-mouse IgG labeled
with fluorescein-isothiocyanate (FITC) and tetramethyl-
rhodamin (TRIC), F(ab')2 fragments of goat anti-rabbit IgG
labeled with FITC, and goat anti-mouse IgG labeled with
peroxidase. Goat anti-mouse IgG conjugated with colloidal gold
(particle size: 15 nm) was obtained from E-Y Laboratories (San
Mateo, California, USA).
Immunocytochemistry
Indirect immunofluorescence and dual staining were per-
formed as described previously [20—23]. In the dual staining,
FITC-labeled goat anti-mouse IgG and TRIC-labeled goat anti-
rabbit IgG were used. The number of glomeruli evaluated
ranged 1 to 10 (mean, 3.4). The intensity and distribution of
fluorescence in each glomerulus were scored as negative (score
0), and 1+ positive (score 1) or 2+ positive (score 2) (Fig. 1, A,
B and C). The mean score (the sum of scores/the number of
glomeruli evaluated) was calculated for each patient. To ana-
lyze the relationship between apoprotein deposition and histo-
logic changes, plasma lipid profile and clinical findings, the
patients were divided into three groups: Group 1, negative
immunofluorescence (score 0); Group 2, weak immunofluores-
cence (mean score 0<  1.5); and Group 3, strong immunoflu-
orescence (mean score 1.5< 2).
As controls, kidney sections were incubated with nonimmune
sera or with unrelated mouse IgG monoclonal antibody, fol-
lowed by incubation with FITC- or TRIC-labeled goat anti-
mouse IgG, or with secondary antibody alone. These controls
were negative.
Immunoelectron microscopy was performed using pre-em-
bedding and post-embedding method as described previously
[21, 23]. For pre-embedding staining [21], tissues were fixed in
paraformaldehyde-lysine-periodate fixative and then embedded
in OCT compound. Then they were incubated with the primary
antibodies, followed by reaction with the appropriate secondary
antibody labeled with peroxidase. The sections were then
treated with diaminobenzidine/hydrogen peroxide solution,
post-fixed with osmic acid, and embedded in Epon 812. Ultra-
thin sections prepared by microtome were observed under an
electron microscope. For the post-embedding method [23],
specimens were embedded in Lowicryl K4M (Chemische
Werke Lowi GmbH, Waldkreiburg, Germany). Ultra-thin sec-
tions, placed on 200-mesh nickel grids, were incubated with
primary antibodies and then reacted with secondary antibodies
labeled with gold particles. The sections were then fixed in 0.2%
glutaraldehyde/0.2 M sodium cacodylate buffer, stained with
uranyl acetate, and viewed under an electron microscope.
Statistical analysis
The correlation between the grade of apoprotein immunoflu-
orescence and that of mesangial proliferation was assessed
using the chi-square test. The relationship between apoprotein
immunofluorescence and plasma levels of total cholesterol,
a
- 
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Fig. 2. Ultrastructural observation of apo B
in glomeruli of patients with focal glomerular
sclerosis (A) and IgA nephritis (B), stained
with monoclonal antibody to apo B-100 and
peroxidase-labeled secondary antibody. A.
Apo B-positive droplets are seen within the
cytoplasm of visceral epithelial cells
(arrowheads). B. Granular reaction products
(asterisks) accumulated in the mesangial
matrix. Original magnification: A x8,000, B
x4,000. Abbreviations are: CL, glomerular
capillary lumen; EP, glomerular epithelial cell;
MC, mesangial cell.
triglyceride, HDL cholesterol, apo A-I, apo B, and apo E, and
24-hour urinary protein excretion and creatinine clearance was
evaluated using the Kruskal-Wallis test. A value less than 0.05
was considered statistically significant.
Results
Apolipoproteins
Apo B and apo E immunofluorescence were not detected in
the glomeruli of normal human kidneys, but were detected
focally in the media of arterioles and peritubular capillaries.
These apolipoproteins were frequently observed in the glomer-
uli of patients with IgA nephritis, mesangial proliferative (non-
IgA) nephritis, Henoch-SchOnlein purpura nephritis, focal gb-
merular sclerosis and lupus nephritis, but were rarely observed
in minimal change nephrotic syndrome (Table 2). Apo B and
apo E were localized predominantly in the mesangium (Fig. 1),
and the distribution and intensity of their fluorescence cone-
lated significantly with the grade of mesangial proliferation (P <
0.05). Apo B (Fig. 1C) and apo E were also stained in sclerosed
areas of glomeruli. Immunoelectron microscopy revealed that
apo B- and apo E-positive droplets were present in the cyto-
plasm of glomerular epithelial cells in focal glomerular sclerosis
(Fig. 2A), and in the cytoplasm of mesangial cells in mesangial
proliferative types of glomerulonephritis. In addition, apo B
(Fig. 2B) and apo E were found as amorphous aggregations in
the mesangial area.
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Fig. 3. Immunofluorescent micrographs of ape A-I in normal and nephritic kidneys. A. Apo A-I is stained dominantly in the glomerular epithelial
cells of the normal human kidney. B. Ape A-I staining is increased in a glomerulus of minimal change nephritic syndrome. C and D. Dual staining
of apo A-I (C) and laminin (D) in a glomerulus of focal glomerular sclerosis. Apo A-I staining is decreased in the sclerosed area (arrows) where
laminin staining is intense. Original magnification: A—D x400.
Fig. 4. Dual immunofluorescent staining of LDL receptor (A) and apo B (B) in a glomerulus of a patient with IgA nephritis. Mesangial
co-localization of LDL receptor and ape B is seen only in the sites stained intensely with apo B (arrows).
Monoclonal antibody to apo A-I stained glomerular epithelial
cells and weakly stained the cytoplasm of some tubular epithe-
hal cells in normal and nephritic human kidneys. The intensity
of the immunofluorescence was increased in the glomeruli of
patients with minimal change nephrotic syndrome, focal gb-
merular sclerosis, and mesangial proliferative types of gbomer-
ulonephritis compared with normal human kidneys, but the
immunofluorescence was reduced or lost in scierosed areas
(Fig. 3). Post-embedding immunoelectron microscopy revealed
that ape A-I was localized in the cytoplasm and foot processes
of visceral epithelial cells.
Oil red 0 staining was performed in 20 sections, and the
results were compared with the immunofluorescent staining for
apo B. The dye was distributed in a scattered fashion, particu-
larly in the mesangial areas of glomeruli and in the renal
interstitium of nephritic kidneys. The distribution of oil red 0
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Fig. S. Immunoelectron microscopic
photographs of LDL receptor in a patient
with IgA nephritis. A. Colloidal gold staining.
Gold particles are distributed on the surface
of foot processes of visceral epithelial cells.
There are small clusters of these particles
(arrows) in some parts (coated pits ?). B.
Peroxidase staining. Reaction products are
seen on the mesangial cell surface (arrows).
Original magnification: A x5,000, B x3,500.
Abbreviations are: BM, glomerular basement
membrane; FP, foot process of glomerular
epithelial cell; MC, mesangial cell.
staining in the mesangial area was similar to that of apo B
staining, but was weaker in intensity and less diffuse than the
latter.
Lipoprotein receptors
In normal human kidneys, LDL receptor immunofluores-
cence was visible in the cytoplasm of tubular epithelial cells,
but was negative in the glomeruli. LDL receptor was positive,
however, in the glomeruli of some patients with glomerular
disease (Table 2). It was distributed predominantly in the
mesangium and weakly along the glomerular capillary walls.
Dual staining showed that LDL receptor was occasionally
co-localized with apo B in the glomeruli, especially in the sites
where apo B staining was intense (Fig. 4). Immunoelectron
microscopy showed that LDL receptor was expressed on the
membrane surface of visceral epithelial cells, as well as on
mesangial cells (Fig. 5).
Weak immunofluorescence for scavenger receptor was de-
tected along the glomerular capillary walls and mesangium of
normal human kidneys. In some of nephritic kidney tissues, the
'4
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Fig. 6. Immunofluorescent photographs of scavenger receptor in patients with IgA nephritis. Dual staining for scavenger receptor (A) and type
IV collagen 7S domain (B) in the same tissue section exhibit distribution of the receptor in the mesangium (arrows) and along the glomerular
capillary walls. Monocyte/macrophage staining in the serial section containing the same glomerulus was negative. Dual staining for scavenger
receptor (C) and monocytes/macrophages (D). The scavenger receptor is intensely expressed by monocytes/macrophages within the glomerulus
(arrows), and is weakly expressed in other parts of the glomerulus. Original magnification: A—D x400. Abbreviation is: G, glomerulus.
expression of scavenger receptor was enhanced in these loci
(Table 2, Fig. 6 A and C). Dual immunofluorescent staining with
anti-scavenger receptor antibody and anti-type IV collagen (7S
domain) antibody confirmed mesangial distribution of the re-
ceptor (Fig. 6 A and B). The immunofluorescence for scavenger
receptor tended to be intense in the glomeruli of patients with
moderate or marked mesangial proliferation. Immunoelectron
microscopic studies further demonstrated that the receptor was
present on the surface of glomerular epithelial and mesangial
cells (Fig. 7 A and B). Dual immunofluorescence for scavenger
receptor and monocytes/macrophages revealed strong expres-
sion of the receptor in monocytes/macrophages which are
occasionally infiltrating the glomeruli of lupus nephritis and IgA
nephritis (Fig. 6 C and D). The localization of scavenger
receptor was generally discordant with that of apo B.
Apolipoprotein deposition and laboratory data
The relationship between apoprotein deposition and labora-
tory findings in patients with mesangial proliferative types of
glomerulonephritis, including IgA nephritis and mesangial pro-
liferative (non-IgA) glomerulonephritis, was evaluated (Table
3). There was no significant correlation between the grade of
glomerular apo B or apo E deposition and plasma levels of total
cholesterol, triglyceride, HDL-cholesterol, apo A-I, apo B, or
apo E. Deposition of apo B and apo E was significantly (P <
0.05) correlated with the patients' 24-hour protein excretion but
not with their creatinine clearance. Since apo A-I immunofluo-
rescence was detected in the glomeruli of normal human
kidneys and was reduced or lost in the scierosed glomeruli in
nephritis tissues, we did not evaluate the relationship between
apo A-I deposition and patients' laboratory data.
Discussion
LDL receptors have been demonstrated on most cell types.
Culture studies have indicated that rat mesangial cells have
specific LDL receptors [7, 9]. Mesangial cells show receptor-
mediated endocytosis of receptor-bound LDL, and high con-
centrations of LDL are toxic to these cells [15, 16]. Cultured
human glomerular epithelial cells also have LDL receptors
which mediate the binding, internalization, and degradation of
LDL [8]. Scavenger receptors [13, 141, different from LDL
receptors in both their binding characteristics and protein
structure, are expressed in a restricted number of cell types.
Whether glomerular mesangial and epithelial cells possess
us
r
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Fig. 7. Immunoelectron microscopy of
scavenger receptor in a patient with IgA
nephritis. A. Colloidal gold staining for
scavenger receptor, displaying labeling of the
foot processes of glomerular epithelial cells.
B. Peroxidase staining for scavenger receptor,
showing labeling of mesangial cells (arrows).
Original magnification: A x 12,000, B x6,000
(inset x8,000). Abbreviations are: BM,
basement membrane in the paramesangial
zone; MES, mesangium; US, urinary space;
MC, mesangial cell.
scavenger receptors is unclear, since they apparently did not
bind and internalize acetylated LDL [8]. However, recent
studies by Coritsidis et al [15] have shown that rat mesangial
cells in culture avidly bind and take up oxidized LDL to a
greater extent than native LDL.
Our present study immunocytochemically demonstrated the
expression of both LDL receptor and scavenger receptor on the
glomerular epithelial and mesangial cells of human kidneys. Our
immunofluorescence study revealed LDL receptor in the gb-
meruli of some patients with glomerulonephritis, particularly in
those with increased mesangial proliferation, although this
receptor was not detected in normal glomeruli. The expression
of scavenger receptor was observed in normal glomeruli, and
was increased in the glomeruli of nephritic kidneys. The gb-
merular expression of LDL receptors was occasionally co-
localized with apo B-lOO, a ligand for the LDL receptor. These
S 
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Tab'e 3. Analysis of the relationship between glomerular apoprotein deposition and plasma lipid level or other laboratory findings in patients
with mesangial proliferative type of glomerulonephritis
Plasma lipid level mg/dl U0,
g124 hr
Ccr
mi/mini
1.73 m2T-C Trig HDL-C Apo A-I Apo B Apo E
Apoprotein B deposition
Group I (N = 3) 154 37 75 7,8 61 0.7 131 14 75 2.3 4.7 1.6 0.55 0.21 95 3.1
Group 2 (N = 8) 148 42 68 27 67 12 120 23 75 14 3.7 0.5 0.85 0.28 89 12
Group 3 (N = 17) 188 48 91 30 63 9.2 131 20 80 22 4.6 1.4 1.8 1.4 85 11P NS NS NS NS NS NS <o.osa NS
Apoprotein E deposition
Group 1 (N = 9) 157 41 71 77 65 12 123 23 72 10 3.8 0.9 0.42 0.30 91 11
Group 2 (N = 9) 155 41 78 14 65 6.1 129 25 72 17 4.3 0.8 0.90 0.84 92 10
Group 3 (N= 10) 198 51 96 37 63 11 131 51 89 23 4.8 1.8 2.3 1.5 80 8.6P NS NS NS NS NS NS <o.osa NS
A total of 28 patients with mesangial proliferative type of glomerulonephritis, consisting of 18 patients with IgA nephritis and 10 with mesangial
proliferative (non-IgA) nephritis, were divided into three groups: Group 1; negative immunofluorescence (score 0); Group 2; weak immunofluo-
rescence (mean score 0< Group 3; strong immunofluorescence (mean score 1.5< Data are expressed as mean SD. Abbreviations
are: T-C, total cholesterol; Trig, triglyceride; HDL-C, HDL cholesterol; urinary protein; Car, creatinine clearance; NS, not statistically
significant,
a Significant correlation between apoprotein deposition and the laboratory finding (the Kruskal-Wallis test analysis)
observations suggest that in vivo glomerular cells in nephntic
conditions can take up both native LDL and modified LDL via
their respective specific receptors.
The oxidization of LDL has been suggested to be a major
contributing factor in the pathogenesis of atherosclerosis [24].
This concept may also be applicable to the glomerular cell
damage found in hyperlipidemic conditions [1—3, 121, which is
similar to the LDL-induced degeneration of smooth muscle
cells. The uptake of oxidized LDL by mesangial cells in culture
could alter eicosanoid synthesis and cytokine production [25],
influencing local hemodynamics and vascular permeability.
Actually, the addition of oxidized LDL to mesangial cells in
culture was shown to increase PGE2 synthesis, while the same
dose of LDL did not have such an effect [15]. Monocytes!
macrophages have been shown to be the dominant immune cell
inifitrating the glomeruli of patients with IgA nephritis, and they
are associated with the magnitude of proteinuria [22, 26]. We
found here that scavenger receptors were also expressed by
monocytes/macrophages identified in the glomeruli of human
nephritis.
Our data show that nephritic kidneys frequently have mesan-
gial accumulations of apo B and apo E. At an ultrastructural
level, these apolipoproteins were observed as droplets within
the cytoplasm of glomerular cells or as amorphous granular
deposits within the mesangial matrix. Similar observations were
previously reported by Sato et al [27], although the sample size
in their study was relatively small and they did not perform
immunoelectron microscopy. Other than being taken up by
specific receptors, apolipoproteins could be deposited simply
by the mechanism of alterations in the mesangial traffic of
macromolecules, or by that of charge affinity to glycosamino-
glycans in the mesangial matrix [28]. They could also be
phagocytosed by mesangial cells [29]. The glomerular deposi-
tion of apo B in the present study was associated with mesangial
expansion in mesangial proliferative types of glomerulonephri-
tis. LDL has been shown to promote the proliferation of
cultured mesangial cells, and, at greater concentrations, to
inhibit this proliferation, showing morphological and biochem-
ical toxicity to these cells [7, 16]. These factors might explain
this association.
We found that apo B-positive droplets were present in the
visceral epithelial cells of patients with focal glomerular sclero-
sis. Abundant lipid vacuoles in gomeruli have been reported in
a patient with idiopathic focal glomerulosclerosis [30]. Verani
and Hawkins [31] found that the presence of foam cells and the
proliferation of epithelial cells were characteristic of the early
lesions of recurrent focal glomerular sclerosis in transplanted
kidneys. The apo B-positive lipid droplets we found in the
visceral epithelial cells might be harmful to these cells, having
an effect similar to that of native or modified LDL on mesangial
cells [15, 16], thus resulting in epithelial cell injury followed by
sclerosis.
Apo A-I is the main apolipoprotein constituent of HDL
cholesterol. Differently from apo B and apo E, we observed apo
A-I predominantly in the visceral epithelial cells. The fluores-
cent intensity of apo A-I was frequently greater in nephritic
kidneys than in normal human kidneys, and was decreased in
sclerosed areas of the glomeruli. Recent studies suggest that the
kidney is the primary site for apo A-I catabolism [32]. As HDL
molecules are too large (molecular wt 330,000) to be filtered
through normal glomerular basement membrane, it is postu-
lated that the free form of apo A-I (molecular wt 28,000) is so
filtered, afterward being reabsorbed predominantly in the prox-
imal tubules. Therefore, apo A-I found in the visceral epithelial
cells may reflect apo A-I that is filtered, even greater in diseased
state, through glomerular basement membrane barrier and
partly absorbed by glomerular epithelial cells. It is not yet
known whether glomerular cells themselves synthesize this
apolipoprotein [33]. Since there was no significant correlation
between the glomerular deposition of apo B and apo E and their
plasma levels, it is unlikely that the glomerular deposition of
apolipoproteins reflects increased levels of these substances in
the circulation, Thus, local factors such as immune-mediated or
non-immune mediated mesangial and epithelial cell injury,
rather than systemic hyperlipidemia, would seem to be impor-
tant for lipid deposition in human glomerulonephritis.
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